Literature DB >> 27317524

The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study.

Hsien-Yi Chiu1, Tsen-Fang Tsai2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27317524     DOI: 10.1016/j.jaad.2016.02.1168

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


× No keyword cloud information.
  3 in total

Review 1.  Novel Biologic Agents Targeting Interleukin-23 and Interleukin-17 for Moderate-to-Severe Psoriasis.

Authors:  Zeyu Chen; Yu Gong; Yuling Shi
Journal:  Clin Drug Investig       Date:  2017-10       Impact factor: 2.859

2.  Perception of the threat, mental health burden, and healthcare-seeking behavior change among psoriasis patients during the COVID-19 pandemic.

Authors:  Hsien-Yi Chiu; Nien-Feng Chang Liao; Yu Lin; Yu-Huei Huang
Journal:  PLoS One       Date:  2021-12-09       Impact factor: 3.240

3.  The seroconversion rate of QuantiFERON-TB Gold In-Tube test in psoriatic patients receiving secukinumab and ixekizumab, the anti-interleukin-17A monoclonal antibodies.

Authors:  Chen-Yu Wu; Hsien-Yi Chiu; Tsen-Fang Tsai
Journal:  PLoS One       Date:  2019-12-27       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.